Hypertonic saline: a novel therapy for advanced heart failure?
暂无分享,去创建一个
[1] A. Tuttolomondo,et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. , 2003, American heart journal.
[2] A. Kurtz,et al. Low tonicity mediates a downregulation of cyclooxygenase-1 expression by furosemide in the rat renal papilla. , 2002, Journal of the American Society of Nephrology : JASN.
[3] L. Stevenson,et al. Medical management of advanced heart failure. , 2002, JAMA.
[4] V. Hasselblad,et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.
[5] J. Daubert,et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.
[6] S. Kaukinen,et al. Hypertonic saline (7.5%) after coronary artery bypass grafting , 2001, European journal of anaesthesiology.
[7] G. Licata,et al. Effects of high‐dose furosemide and small‐volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure , 2000, European journal of heart failure.
[8] M. Drazner,et al. Tailored therapy using dobutamine and nitroglycerin in advanced heart failure. , 1999, The American journal of cardiology.
[9] E. Vicaut,et al. Comparison of the acute hemodynamic effects of hypertonic or colloid infusions immediately after mitral valve repair. , 1999, Critical care medicine.
[10] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[11] Y. Moshkovitz,et al. Increased toxicity of high‐dose furosemide versus low‐dose dopamine in the treatment of refractory congestive heart failure , 1997, Clinical pharmacology and therapeutics.
[12] B Schwilk,et al. Effect of 7.2% Hypertonic Saline/6% Hetastarch on Left Ventricular Contractility in Anesthetized Humans , 1995, Anesthesiology.
[13] Å. Hjalmarson,et al. Beta-blocker treatment for chronic heart failure. The frog prince. , 1994, Circulation.
[14] P. Constable,et al. Hypertonic saline is a negative inotropic agent in normovolumic dogs. , 1994, The American journal of physiology.
[15] D. White,et al. Cardiac contractility and blood flow distribution following resuscitation with 7.5% hypertonic saline in anesthetized dogs. , 1991, Circulatory shock.
[16] M. Luu,et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤ 20% secondary to ischemic or nonischemic dilated cardiomyopathy , 1990 .
[17] S. Bachmann,et al. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. , 1985, The American journal of physiology.
[18] I. Velasco,et al. TREATMENT OF REFRACTORY HYPOVOLÆMIC SHOCK BY 7·5% SODIUM CHLORIDE INJECTIONS , 1980, The Lancet.
[19] M. Drazner,et al. Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure. , 2002, American heart journal.
[20] W. Pfaller,et al. Inhibition of angiotensin-converting enzyme modulates structural and functional adaptation to loop diuretic-induced diuresis. , 1997, Kidney international.